Related Experiment Videos
Topoisomerase II as a target of antileukemic drugs
Abstract:
The identification of topoisomerase II as a target of antineoplastic drug therapy is traced from the original observations by Ross et al. (1,2) in murine leukemia cells through studies with m-AMSA-resistant human leukemia cells. Recently developed quantitative biochemical assays of topoisomerase II activity and the susceptibility of topoisomerase II to the effects of m-AMSA have allowed the principles identified in murine and human leukemia cell culture systems to be applied to clinical material; a prospective trial is testing the utility of such assays for individualizing antineoplastic drug therapy.
Insights
Topoisomerase II is a key target for cancer drugs. New assays measure its activity, aiding personalized cancer treatment strategies in clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Topoisomerase II (an enzyme crucial for DNA replication and repair) was identified as a target for antineoplastic (cancer-fighting) drug therapy.
- Early research in murine leukemia cells and m-AMSA-resistant human leukemia cells established this enzyme's role.
Purpose of the Study:
- To trace the identification of topoisomerase II as a therapeutic target.
- To evaluate the application of biochemical assays for individualizing antineoplastic drug therapy.
Main Methods:
- Utilizing quantitative biochemical assays to measure topoisomerase II activity.
- Assessing the susceptibility of topoisomerase II to drugs like m-AMSA.
- Applying findings from cell culture systems (murine and human leukemia) to clinical settings.
Main Results:
- Established principles linking topoisomerase II activity and drug response in leukemia models.
- Demonstrated the feasibility of applying these principles to clinical material.
Conclusions:
- Quantitative assays for topoisomerase II activity and drug susceptibility are valuable tools.
- These assays show promise for personalizing antineoplastic drug therapy in cancer patients.